Quote | Medexus Pharmaceuticals Inc. (TSXC:MDP:CC)
Last: | $2.31 |
---|---|
Change Percent: | 0.0% |
Open: | $2.31 |
Close: | $2.31 |
High: | $2.31 |
Low: | $2.3 |
Volume: | 3,802 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Medexus Pharmaceuticals Inc. (TSXC:MDP:CC)
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®. Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) and medac, licensor of Medexus's c...
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024. Event : ...
Message Board Posts | Medexus Pharmaceuticals Inc. (TSXC:MDP:CC)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Medexus Pharmaceuticals Inc. Company Name:
MDP:CC Stock Symbol:
TSXC Market:
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®. Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) and medac, licensor of Medexus's c...
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024. Event : ...
Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age group Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 26, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) to...